Pattern of adverse drug reactions experienced by tuberculosis patients in a tertiary care teaching hospital in Western Nepal

Pakistan Journal of Pharmaceutical Sciences

Volumn 21, Issue 1, 2008, Pages 51-56

  Kishore, P V ^a   Palaian, Subish ^a   Ojha, Pradip ^a   Shankar, P R ^a  

^a MANIPAL TEACHING HOSPITAL   (Nepal)

Author keywords

Adverse drug reactions; Anti tubercular treatment; Nepal; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT; ASPARTATE AMINOTRANSFERASE;

ADULT; ARTHRALGIA; ARTICLE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG ERUPTION; DRUG SAFETY; ERYTHEMA; FEMALE; GASTRITIS; HEPATITIS; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPAL; NEURITIS; SIDE EFFECT; TEACHING HOSPITAL; TERTIARY HEALTH CARE; TREATMENT OUTCOME; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; VESTIBULAR NEURONITIS; VISUAL IMPAIRMENT; VOMITING; AGED; BLOOD; DIRECTLY OBSERVED THERAPY; DRUG SURVEILLANCE PROGRAM; HOSPITALIZATION; LIVER FUNCTION TEST; LUNG TUBERCULOSIS; MIDDLE AGED; POLYPHARMACY; RETROSPECTIVE STUDY; TOXIC HEPATITIS;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; ASPARTATE AMINOTRANSFERASES; DIRECTLY OBSERVED THERAPY; FEMALE; HEPATITIS, TOXIC; HOSPITALS, TEACHING; HUMANS; ISONIAZID; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; NEPAL; POLYPHARMACY; PYRAZINAMIDE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TUBERCULOSIS, PULMONARY;

EID: 41649108100     PISSN: 1011601X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Anupa KC (2006). A study of adverse drug reactions caused by first line anti-tubercular drugs used in Directly Observed Treatment, Short course (DOTS) therapy in western Nepal, Pokhara. A thesis submitted to the Kathmandu University, Kathmandu, Nepal.
2. BTS guidelines (1998). Chemotherapy and management of tuberculosis in the United Kingdom: Recommendations. Thorax, 53: 536-548.
3. Chukanov VI, Kaminskaia GO and Livchane E (2004). Frequency and pattern of adverse reactions due to treatment of patients with pulmonary tuberculosis with antitubercular reserve drugs. Probl Tuberk Bolezn Legk., 10: 6-10.
4. Dhingra VK, Rajpal S, Aggarwal N, Aggarwaln JK, Shadab K and Jain SK (2004). Adverse drug reactions observed during DOTS. J. Commun. Dis., 36(4): 251-259. (Pubitemid 43116792)
5. Harries A, Maher D and Uplekar M (1998). National Tuberculosis Program of Nepal. A clinical manual. National Tuberculosis Center, Thimi, Bhaktapur, Nepal.
6. Hartwig SC, Siegel J and Schneider PJ (1992). Preventability and severity assessment in reporting adverse drug reactions. Am. J. Hosp. Pharm., 49: 2229-2232.
7. Mishin VIu, Vasil'eva IA, Makieva VG, Kuz'mina NV, Prikazchikova AV and Khoroshutina VV (2003). Frequency, pattern, and diagnosis of adverse reactions in patients with pulmonary tuberculosis during chemotherapy with leading drugs. Probl Tuberk Bolezn Legk., 7: 24-29.
8. Naranjo CA, Busto U and Sellers EM (1981). A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther., 30: 239-245.
9. National Tuberculosis Centre (2000/2001). Annual Report of National Tuberculosis Control Programme, Nepal.
10. National Tuberculosis Centre (2004). Annual report of tuberculosis control programme (2002/2003). Thimi, Bhaktapur, Nepal: Department of Health Services, Ministry of Health, His Majesty's Government of Nepal.
11. rd edition. Edinburgh: Churchill Livingston, pp.583-595.
12. Ormerod LP and Horsfield N (1996). Frequency and type of reactions to anti-tuberculosis drugs: observations in routine treatment. Tuber Lung Dis., 77(1): 37-42.
13. Puavilai S and Timpatanapong P (1989). Prospective study of cutaneous drug reactions. J. Med. Assoc. Thai., 72: 167-171.
14. Rossouw JE and Saunders SJ (1975). Hepatic complications of anti-tuberculous therapy. Q. J. Med., 44(173): 1-16.
15. Shakya R and Rao BS (2004). Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors. Ann. Pharmacother., 38(6): 1074-1079.
16. Shrestha R, Shakya S and Bista D (2006). Case studies of hospitalized patients due to drug related complications. Kathmandu Univ. J. Sci. Eng. Technol. http://www.ku. edu.np/kuset/second-issue/o2/Rajeev.pdf.
17. Tashpulatova FK (2003). Prevention of adverse reactions of antituberculous drugs in pulmonary tuberculosis in patients with different genetic background. Probl Tuberk Bolezn Legk., (6): 17-20.
18. van der Werf TS, Dade GK and van der Mark T (1990). Patient compliance with tuberculosis treatment in Ghana: factors influencing adherence to therapy in a rural service program. Tubercle., 71: 247-252.
19. Wada M (1998). The adverse reactions of antituberculosis drugs and its management. Nippon Rinsho., 56 (12): 3091-3095.
20. Wilson K (1984). Sex-related difference in drug disposition in man, Clinical. Pharmacokinet., 9: 189-202.
21. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I and Menzies D (2003). Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am. J. Respir. Crit. Care Med., 167(11): 1472-1477. (Pubitemid 37363354)
22. Yew WW and Leung CC (2006). Anti-tuberculosis drugs and hepatotoxicity. Respirology., 11(6): 699-707.